Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 857

1.

Normal Growth and Essential Fatty Acid Status in Children with Intestinal Failure on Lipid Limitation.

Lam G, Strogach I, Baron N, Thompson JF.

J Pediatr Gastroenterol Nutr. 2015 Aug 20. [Epub ahead of print]

PMID:
26301616
2.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.

EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.

3.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

4.

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV.

Cancer. 2015 Jul 28. doi: 10.1002/cncr.29586. [Epub ahead of print]

PMID:
26218930
5.

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.

Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.

Lancet Oncol. 2015 Jul 20. pii: S1470-2045(15)00187-4. doi: 10.1016/S1470-2045(15)00187-4. [Epub ahead of print]

PMID:
26206146
6.

Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1 mm) Sentinel Lymph Node Metastases.

Holtkamp LH, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA.

Ann Surg Oncol. 2015 Sep;22(9):2972-7. doi: 10.1245/s10434-015-4615-z. Epub 2015 May 20.

PMID:
25990968
7.

How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center?

Memari N, Hayen A, Bell KJ, Rychetnik L, Morton RL, McCaffery K, Thompson JF, Irwig L, Turner RM.

Ann Surg Oncol. 2015 May 12. [Epub ahead of print]

PMID:
25963479
8.

Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center.

Haydu LE, Stollman JT, Scolyer RA, Spillane AJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Bonenkamp JJ, Thompson JF.

Ann Surg Oncol. 2015 May 9. [Epub ahead of print]

PMID:
25956574
9.

First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.

Fogarty GB, Hong A, Dolven-Jacobsen K, Reisse CH, Burmeister B, Haydu LH, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer RA, Mandel C, Thompson JF.

BMC Res Notes. 2015 May 8;8:192. doi: 10.1186/s13104-015-1153-5.

10.

Should patients with melanoma brain metastases receive adjuvant whole-brain radiotherapy?

Fogarty GB, Hong A, Thompson JF.

Lancet Oncol. 2015 May;16(5):e195-6. doi: 10.1016/S1470-2045(15)70183-X. No abstract available.

PMID:
25943057
11.

Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery.

Yang Y, Salayandia VM, Thompson JF, Yang LY, Estrada EY, Yang Y.

J Neuroinflammation. 2015 Feb 10;12:26. doi: 10.1186/s12974-015-0245-4.

12.

BAP1-inactivated spitzoid naevi.

Vilain RE, McCarthy SW, Thompson JF, Scolyer RA.

Am J Surg Pathol. 2015 May;39(5):722. doi: 10.1097/PAS.0000000000000407. No abstract available.

PMID:
25871468
13.

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.

Wilmott JS, Colebatch AJ, Kakavand H, Shang P, Carlino MS, Thompson JF, Long GV, Scolyer RA, Hersey P.

Mod Pathol. 2015 Jul;28(7):884-94. doi: 10.1038/modpathol.2015.34. Epub 2015 Apr 3.

PMID:
25836739
14.

Punch biopsy of melanoma causing tumour cell implantation: Another peril of utilising partial biopsies for melanocytic tumours.

Luk PP, Vilain R, Crainic O, McCarthy SW, Thompson JF, Scolyer RA.

Australas J Dermatol. 2015 Aug;56(3):227-31. doi: 10.1111/ajd.12333. Epub 2015 Mar 31.

PMID:
25827527
16.

The Contemporary Role of Major Amputation in the Management of Advanced Limb Melanoma.

Read RL, Stalley P, Thompson JF.

Ann Surg Oncol. 2015 Feb 25. [Epub ahead of print]

PMID:
25712799
17.

Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP.

Jalal FY, Yang Y, Thompson JF, Roitbak T, Rosenberg GA.

J Cereb Blood Flow Metab. 2015 Jul;35(7):1145-53. doi: 10.1038/jcbfm.2015.21. Epub 2015 Feb 25.

PMID:
25712499
18.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.

Ann Oncol. 2015 Jun;26(6):1118-23. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20.

PMID:
25701452
19.

Imaging sentinel lymph nodes.

Uren RF, Howman-Giles R, Chung D, Thompson JF.

Cancer J. 2015 Jan-Feb;21(1):25-32. doi: 10.1097/PPO.0000000000000092.

PMID:
25611777
20.

The history of sentinel lymph node biopsy.

Nieweg OE, Uren RF, Thompson JF.

Cancer J. 2015 Jan-Feb;21(1):3-6. doi: 10.1097/PPO.0000000000000091.

PMID:
25611772
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk